Kintegral Advisory LLC Sells 57,229 Shares of Pfizer Inc. (NYSE:PFE)

Kintegral Advisory LLC reduced its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 32.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 116,688 shares of the biopharmaceutical company's stock after selling 57,229 shares during the period. Kintegral Advisory LLC's holdings in Pfizer were worth $2,957,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Beam Wealth Advisors Inc. increased its stake in Pfizer by 1.5% in the 4th quarter. Beam Wealth Advisors Inc. now owns 27,444 shares of the biopharmaceutical company's stock worth $728,000 after acquiring an additional 401 shares during the last quarter. Providence Capital Advisors LLC boosted its position in shares of Pfizer by 0.4% during the 4th quarter. Providence Capital Advisors LLC now owns 114,358 shares of the biopharmaceutical company's stock valued at $3,034,000 after acquiring an additional 409 shares during the last quarter. Donaldson Capital Management LLC grew its holdings in shares of Pfizer by 1.2% in the fourth quarter. Donaldson Capital Management LLC now owns 35,694 shares of the biopharmaceutical company's stock valued at $947,000 after purchasing an additional 410 shares in the last quarter. William B. Walkup & Associates Inc. increased its position in Pfizer by 1.2% in the fourth quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company's stock worth $1,044,000 after purchasing an additional 454 shares during the last quarter. Finally, Balboa Wealth Partners raised its stake in Pfizer by 1.6% during the fourth quarter. Balboa Wealth Partners now owns 30,678 shares of the biopharmaceutical company's stock valued at $814,000 after purchasing an additional 480 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

PFE has been the subject of a number of recent research reports. Redburn Atlantic dropped their price objective on shares of Pfizer from $29.00 to $27.00 and set a "neutral" rating for the company in a research note on Wednesday, April 30th. BMO Capital Markets reduced their price objective on Pfizer from $36.00 to $30.00 in a research note on Thursday, April 17th. Morgan Stanley upped their price objective on Pfizer from $31.00 to $32.00 and gave the company an "equal weight" rating in a research report on Wednesday, April 30th. The Goldman Sachs Group lifted their target price on Pfizer from $25.00 to $27.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Finally, Jefferies Financial Group increased their price target on Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a report on Wednesday, May 21st. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, Pfizer currently has a consensus rating of "Hold" and a consensus target price of $28.55.

Pfizer Stock Up 0.5%

Shares of PFE opened at $25.45 on Friday. The firm has a fifty day moving average price of $23.67 and a 200-day moving average price of $24.84. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. The firm has a market capitalization of $144.66 billion, a P/E ratio of 18.44, a P/E/G ratio of 0.92 and a beta of 0.58. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. The company had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The firm's revenue for the quarter was down 7.8% on a year-over-year basis. During the same quarter last year, the business posted $0.82 EPS. Equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.76%. Pfizer's payout ratio is 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.